IDH2 and central nervous system cancer: A bimodal DNA and RNA next-generation sequencing panel for integrative diagnosis of glioma (7, 29) was performed (IRB approval #C2023-0039), and IDH2 R172S mutation (variant allele frequency [VAF] 48.1%), as well as TP53 C275F (VAF 91.2%) and ATRX c.3809 + 1G>C (VAF 92.1%), were detected.